Close Menu

Genentech

The FDA-approved complementary assay "can provide insight into the survival benefit that may be achieved" with the treatment, Roche said.

The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.

Pages